6IQG image
Entry Detail
PDB ID:
6IQG
Keywords:
Title:
X-ray crystal structure of Fc and peptide complex
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2018-11-08
Release Date:
2019-02-13
Method Details:
Experimental Method:
Resolution:
3.00 Å
R-Value Free:
0.27
R-Value Work:
0.19
R-Value Observed:
0.20
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Immunoglobulin gamma-1 heavy chain
Chain IDs:A, B
Chain Length:210
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:18-mer peptide G(HCS)DCAYHRGELVWCT(HCS)H(NH2)
Chain IDs:C, D
Chain Length:18
Number of Molecules:2
Biological Source:synthetic construct
Ligand Molecules
Primary Citation
Site-Specific Chemical Conjugation of Antibodies by Using Affinity Peptide for the Development of Therapeutic Antibody Format.
Bioconjug. Chem. 30 698 702 (2019)
PMID: 30606013 DOI: 10.1021/acs.bioconjchem.8b00865

Abstact

Artificially modified IgG molecules are increasingly utilized in industrial and clinical applications. In the present study, the method of chemical conjugation by affinity peptide (CCAP) for site-specific chemical modification has been developed by using a peptide that bound with high affinity to human IgG-Fc. This method enabled a rapid modification of a specific residue (Lys248 on Fc) in a one-step reaction under mild condition to form a stable amide bond between the peptide and Fc. The monovalent peptide-IgG conjugate not only maintained complete antigen binding but also bound to Fc receptors (FcRn, FcγRI, and FcγRIIIa), indicating that it is a suitable conjugate form that can be further developed into highly functional antibody therapeutics. CCAP was applied for the preparation of an antibody-drug conjugate and a bispecific antibody to demonstrate the usefulness of this method.

Legend

Protein

Chemical

Disease

Primary Citation of related structures